Granted Patent B2

US 12,460,264 · App. 16/347,134 · Granted Nov 4, 2025

Inventors: Robert Charles Swanton (London, GB); Christopher Abbosh (Herts, GB)

Assignees: Natera, Inc.; UCL Business PLC

C12Q1/6886C12Q1/686C12Q2600/106C12Q2600/118C12Q2600/156C12Q2600/16

Abstract

Claims (27)

1 . A method for treatment of lung squamous cell carcinoma in a subject, the method comprising:

a) sequencing all of a genome of the lung squamous cell carcinoma of the subject to define early clonal mutations in said lung squamous cell carcinoma, wherein said sequencing is carried out on one or more samples obtained from all or part of the lung squamous cell carcinoma or one or more subsections thereof and defining the early clonal mutations comprises:

1) calculating an observed cancer cell fraction (CCF) of each mutation (obsCCF) and a phylogenetic CCF of that mutation (phyloCCF);

2) timing a clonal or subclonal mutation using the phyloCCF, wherein mutations in parts of the genome with at least two copies of a major allele are preliminarily classified as early if a mutation copy number for the mutation is greater than 1 and as late if the mutation copy number for the mutation is less than or equal to 1; and

3) performing temporal analysis comprising classifying all clonal or all subclonal mutations that are preliminarily classified as early across all tumor regions as an early clonal mutation, classifying all clonal or all subclonal mutations that are preliminarily classified as late across all tumor regions as a late clonal or subclonal mutation, and classifying all clonal or all subclonal mutations not timed as early or late as being a clonal or subclonal untimed mutation;

b) clustering all the clonal and subclonal mutations;

c) identifying mutation clusters having at least five mutations assigned thereto;

d) producing a subject-specific fraction of DNA by identifying the lung squamous cell carcinoma samples having at least two mutation clusters identified therein;

e) performing phylogenetic analysis on the subject-specific fraction of the DNA, wherein the phylogenetic analysis comprises assembling the mutations into a phylogenetic tree defining the clonal and subclonal mutation profile of the lung squamous cell carcinoma;

f) analyzing DNA included in a sample of DNA obtained from the subject subsequent to the lung squamous cell carcinoma removal using a set of subject-specific reagents capable of detecting at least one early clonal mutation characteristic of a trunk of the phylogenetic tree and at least one subclonal mutation characteristic of a branch of the phylogenetic tree, wherein detecting the at least one subclonal mutation characteristic of the branch of the phylogenetic tree is indicative of the branch seeding a relapse of the lung squamous cell carcinoma in the subject; and

g) administering a treatment to the subject, wherein the treatment comprises adjuvant chemotherapy and is a personalized treatment chosen for the subject in order to target the branch seeding the relapse of the lung squamous cell carcinoma in the subject; and

h) monitoring a response of the subject to the treatment based on detection of the at least one early clonal mutation characteristic of the trunk of the phylogenetic tree.

2 . The method according to claim 1 , wherein said sequencing is carried out on said lung squamous cell carcinoma or subsection thereof following removal of the lung squamous cell carcinoma.

3 . The method according to claim 1 , wherein the sample of DNA obtained from the subject subsequent to the lung squamous cell carcinoma removal comprises cfDNA, circulating lung squamous cell carcinoma DNA, exosome derived lung squamous cell carcinoma DNA, or circulating lung carcinoma cells.

4 . The method of claim 1 , wherein all of the genome of at least two subsections of the lung squamous cell carcinoma is sequenced and clonal and subclonal mutations are defined based on which mutations occur in which lung squamous cell carcinoma subsections.

5 . The method of claim 4 , wherein the clonal and subclonal mutations in the lung squamous cell carcinoma are defined by sequencing the genome of up to ten subsections of the lung squamous cell carcinoma.

6 . The method of claim 1 , wherein the clonal and subclonal mutations are single nucleotide variant (SNV) mutations.

7 . The method of claim 1 , wherein said set of reagents is a set of multiplex PCR primers and said analysis is a multiplex PCR.

8 . The method of claim 1 , further comprising synthesising said set of reagents.

9 . The method of claim 1 , further comprising sequencing all of the lung squamous cell carcinoma genome of the subject and comparing this with said lung squamous cell carcinoma genome sequences to define the clonal and subclonal mutations found in the subject's lung squamous cell carcinoma.

10 . The method of claim 1 , wherein said set of detection reagents detects at least one or at least two clonal mutations.

11 . The method of claim 1 , wherein said set of detection reagents detects at least one mutation characteristic of each subsection of the lung squamous cell carcinoma.

12 . The method according to claim 1 , wherein the whole genome of said DNA from said lung squamous cell carcinoma and of the subject is sequenced.

13 . The method of claim 1 , wherein the genome is sequenced to identify the early clonal mutations from the subject's lung squamous cell carcinoma in the subject's cfDNA.

14 . The method of claim 1 , wherein the said sequencing is carried out on blood plasma obtained from the subject, or said sample to be analysed is a blood plasma sample from the subject; and wherein said subject is a human subject.

15 . The method of claim 1 , wherein the analysis is carried out at least 48 hours, from 48 hours to 7 days, from 7 to 14 days, from 14 days to one month, from one to two months, from two to six months, from six months to one year or over one year from the removal of the lung squamous cell carcinoma; and wherein the analysis of (d) is carried out on multiple occasions times over a period of time.

16 . The method of claim 1 , wherein the analysis of (d) comprises multiplex PCR followed by next-generation sequencing with an average target depth of reads of at least 40,000.

Assignments (2)

Priority Claims (1)

Continuity (1)

References Cited (400)